Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Richman

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Plos One|July 24, 2008
Type I interferon: potential therapeutic target for psoriasis?Yihong Yao, Laura Richman, Chris Morehouse, et al.
Pigment Cell & Melanoma Research|December 3, 2013
MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin DRobert W Georgantas, Katie Streicher, Xiaobing Luo, et al.
Arthritis and Rheumatism|May 30, 2009
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosusYihong Yao, Laura Richman, Brandon W Higgs, et al.
BMC Medical Genomics|November 23, 2012
Genomic signatures characterize leukocyte infiltration in myositis musclesWei Zhu, Katie Streicher, Nan Shen, et al.
Annals of the Rheumatic Diseases|August 2, 2011
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathwayBrandon W Higgs, Zheng Liu, Barbara White, et al.
Plos One|November 3, 2011
Altered expression of insulin receptor isoforms in breast cancerJiaqi Huang, Chris Morehouse, Katie Streicher, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 24, 2014
Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathiesRobert W Georgantas, Katie Streicher, Steven A Greenberg, et al.
Annals of the Rheumatic Diseases|July 30, 2011
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised studyJoan T Merrill, Daniel J Wallace, Michelle Petri, et al.
Annals of the Rheumatic Diseases|February 26, 2013
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patientsBrandon W Higgs, Wei Zhu, Chris Morehouse, et al.
Human Gene Therapy|August 27, 2020
Adeno-Associated Virus-Induced Dorsal Root Ganglion PathologyJuliette Hordeaux, Elizabeth L Buza, Cecilia Dyer, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Plos One|July 24, 2008
Type I interferon: potential therapeutic target for psoriasis?Yihong Yao, Laura Richman, Chris Morehouse, et al.
Pigment Cell & Melanoma Research|December 3, 2013
MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin DRobert W Georgantas, Katie Streicher, Xiaobing Luo, et al.
Arthritis and Rheumatism|May 30, 2009
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosusYihong Yao, Laura Richman, Brandon W Higgs, et al.
BMC Medical Genomics|November 23, 2012
Genomic signatures characterize leukocyte infiltration in myositis musclesWei Zhu, Katie Streicher, Nan Shen, et al.
Annals of the Rheumatic Diseases|August 2, 2011
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathwayBrandon W Higgs, Zheng Liu, Barbara White, et al.
Plos One|November 3, 2011
Altered expression of insulin receptor isoforms in breast cancerJiaqi Huang, Chris Morehouse, Katie Streicher, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 24, 2014
Inhibition of myogenic microRNAs 1, 133, and 206 by inflammatory cytokines links inflammation and muscle degeneration in adult inflammatory myopathiesRobert W Georgantas, Katie Streicher, Steven A Greenberg, et al.
Annals of the Rheumatic Diseases|July 30, 2011
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised studyJoan T Merrill, Daniel J Wallace, Michelle Petri, et al.
Annals of the Rheumatic Diseases|February 26, 2013
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patientsBrandon W Higgs, Wei Zhu, Chris Morehouse, et al.
Human Gene Therapy|August 27, 2020
Adeno-Associated Virus-Induced Dorsal Root Ganglion PathologyJuliette Hordeaux, Elizabeth L Buza, Cecilia Dyer, et al.
Pageof 3